- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00107172
Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High Risk Patients With Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To ascertain whether patients treated by sublobar resection (SR) + brachytherhapy (BX) have longer time to local recurrence as compared to the patients treated by SR (local recurrence includes recurrence within the same lobe or hilum [N1 nodes], or progression at the staple line after treatment effects such as scarring have subsided).
SECONDARY OBJECTIVES:
I. To compare procedure specific morbidity and mortality between study arms. II. To compare overall survival and failure-free survival between study arms. III. To assess freedom from regional or distant recurrence. IV. To assess the effect of histological or cytologic positive resection margins on time to local recurrence.
V. To determine the effect of brachytherapy on quality of life (QoL). VI. To determine the effect of brachytherapy on pulmonary function.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
ARM II: Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising iodine I 125 implant at the resection margin.
After completion of study treatment, patients are followed at 3, 6, 12, 18, 24, 30, and 36 months and then yearly for 2 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Ontario
-
London, Ontario, Kanada, N6A 4L6
- London Regional Cancer Program at London Health Sciences Centre
-
-
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259-5499
- Mayo Clinic Scottsdale
-
-
California
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Cancer Center
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic - Jacksonville
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Winship Cancer Institute of Emory University
-
-
Illinois
-
Evanston, Illinois, Vereinigte Staaten, 60201-1781
- Evanston Hospital
-
Springfield, Illinois, Vereinigte Staaten, 62781-0001
- Regional Cancer Center at Memorial Medical Center
-
Springfield, Illinois, Vereinigte Staaten, 62794-9677
- Simmons Cooper Cancer Institute
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Cancer Institute at St. John's Hospital
-
-
Maryland
-
Towson, Maryland, Vereinigte Staaten, 21204
- Cancer Institute at St. Joseph Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston University Cancer Research Center
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109-0942
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Ridgewood, New Jersey, Vereinigte Staaten, 07450
- Valley Hospital - Ridgewood
-
-
New York
-
Oceanside, New York, Vereinigte Staaten, 11572
- South Nassau Communities Hospital
-
Rochester, New York, Vereinigte Staaten, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- Charles M. Barrett Cancer Center at University Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239-3098
- Knight Cancer Institute at Oregon Health and Science University
-
-
Pennsylvania
-
New Castle, Pennsylvania, Vereinigte Staaten, 16105
- Jameson Memorial Hospital - North Campus
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Cancer Centers
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny Cancer Center at Allegheny General Hospital
-
Reading, Pennsylvania, Vereinigte Staaten, 19612-6052
- McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02906
- Miriam Hospital
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920-6999
- U.T. Medical Center Cancer Institute
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Methodist Hospital
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84157
- Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98122-4307
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Seattle, Washington, Vereinigte Staaten, 98111
- Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-6164
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- PART I: PRE-OPERATIVE CRITERIA (PRE-REGISTRATION/RANDOMIZATION)
- Patients must have a suspicious lung nodule for clinical stage I non-small cell lung cancer (NSCLC)
- Patient must have a mass =< 3 cm maximum diameter by computed tomography (CT) size estimate: clinical stage Ia or selected Ib (i.e., with visceral pleural involvement)
- Patient must have a CT scan of the chest with upper abdomen within 60 days prior to date of pre-registration
- Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0, 1, or 2
Patient must meet at least one major criteria or meet a minimum of two minor criteria as described below:
Major criteria
- Forced expiratory volume in 1 second (FEV1) =< 50% predicted
- Diffusing capacity of the lungs for carbon monoxide (DLCO) =< 50% predicted
Minor criteria
- Age >= 75
- FEV1 51-60% predicted
- DLCO 51-60% predicted
- Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40 mmHg) as estimated by echocardiography or right heart catheterization
- Poor left ventricular function (defined as an ejection fraction of 40% or less)
- Resting or exercise partial pressure of oxygen (pO2) =< 55 mm Hg or peripheral capillary oxygen saturation (SpO2) =< 88%
- Partial pressure of carbon dioxide (pCO2) > 45 mm Hg
- Modified Medical Research Council (MMRC) Dyspnea Scale >= 3
- Patient must not have had previous intra-thoracic radiation therapy
- Women of child-bearing potential must have negative serum or urine pregnancy test
- No prior invasive malignancy, unless disease-free for >= 5 years prior to pre-registration (exceptions: non-melanoma skin cancer, in-situ cancers)
- PART II: INTRA-OPERATIVE CRITERIA (REGISTRATION)
- Patient must have biopsy-proven NSCLC
- Patient must have all suspicious mediastinal lymph nodes (> 1 cm short-axis dimension on CT scan or positive on positron emission tomography [PET] scan) assessed by one of the following methods to confirm negative involvement with NSCLC (mediastinoscopy, endo-esophageal ultrasound guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Arm I
Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
|
|
Experimental: Arm II
Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to Local Recurrence
Zeitfenster: Up to 3 years
|
Local recurrence included the recurrence within the same lobe or hilum (N1 nodes), or progression at the staple line after treatment effects such as scarring have subsided.
Time to local recurrence was censored 1) at the time of a distant recurrence, 2) at the last follow-up time when a patient died within 3 years of randomization without a local recurrence or 3) at 3 years follow-up if the patient remains alive 3 years post-randomization without a local recurrence.
|
Up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Survival (OS)
Zeitfenster: Up to 5 years
|
OS was defined as the time from randomization to death due to any cause.
|
Up to 5 years
|
Number of Participants Reported Local Recurrence at 3 Years
Zeitfenster: 3 years
|
Local recurrence was defined as the recurrence within the same lobe or hilum (N1 nodes), or at the staple line after treatment effects such as scarring have subsided.
|
3 years
|
Number of Participants Reported Regional Recurrence at 3 Years
Zeitfenster: 3 years
|
Regional recurrence was defined as the recurrence within another lobe or pleura on the same side as the resection, or the ipsilateral mediastinal (N2) nodes.
|
3 years
|
Number of Participants Reported Distant Recurrence at 3 Years
Zeitfenster: 3 years
|
Distant recurrence was defined as the recurrence within contralateral lobe, contralateral mediastinal (N3) nodes or distant> metastatic disease (other organs).
|
3 years
|
Mortality Rates at 30- and 90-day After Sublobar Resection
Zeitfenster: 90 days
|
90 days
|
|
Number of Participants Reported Grade 3+ Adverse Events Within 90 Days After Sublobar Resection
Zeitfenster: 90 days
|
Adverse Events were assessed via the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
|
90 days
|
Number of Participants Reported Grade 3+ Respiratory Adverse Events Within 90 Days After Sublobar Resection
Zeitfenster: 90 days
|
The respiratory AE included adult respiratory distress syndrome, aspiration, bronchospasm, bronchostenosis, dyspnea, hypoxia, pleural effusion, pneumonitis, chest tube drainage or leak, prolonged intubation, pulmonary-other, and pneumonia as defined by the CTCAE version 3.0.
|
90 days
|
Global QOL as Measured Using SF36 at Baseline, Month 3, 12 and 24
Zeitfenster: 24 months
|
Short-form health survey (SF36) consist of 36 items, where scores can be reported as 8 domains of functional health and well-being, or transformed into a physical component summary (PCS) score and a mental component summary (MCS) score.
Standardized scores of SF36 PCS and MCS scores were calculated using the mean, SD, and scoring coefficients from the US general population.
The standardized scores were then adjusted for age and gender using the mean and SD of the US general population according to age and gender grouping, and employing a linear transformation.
Scores <50 indicate below-average health status.
|
24 months
|
Dyspnea as Measured Using SOBQ at Baseline, Months 3, Months 12 and 24
Zeitfenster: 24 months
|
Dyspnea was evaluated using the University of California, San Diego Shortness of Breath Questionnaire (SOBQ).
It consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness.
The total scores was calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life..
|
24 months
|
FEV1% Measured at Baseline and Month 3
Zeitfenster: 3 months
|
Pulmonary function tests included percentage predicted forced expiratory volume in 1 second (FEV1%) at baseline and month 3 were compared between arms
|
3 months
|
DLCO% Measured at Baseline and Month 3
Zeitfenster: 3 months
|
Pulmonary function tests included percentage predicted carbon > monoxide diffusing capacity of the lung (DLCO%) at baseline and month 3 were compared between arms. |
3 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Hiran C. Fernando, MD, Boston Medical Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Smith RP, Schuchert M, Komanduri K, Burton S, Heron DE, Luketich JD, d'Amato T, Landreneau R. Dosimetric evaluation of radiation exposure during I-125 vicryl mesh implants: implications for ACOSOG z4032. Ann Surg Oncol. 2007 Dec;14(12):3610-3. doi: 10.1245/s10434-007-9624-0. Epub 2007 Oct 2.
- Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron DE, Jones DR, Daly BD, Starnes SL, Tan A, Putnam JB. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg. 2011 Nov;142(5):1143-51. doi: 10.1016/j.jtcvs.2011.07.051. Epub 2011 Aug 26.
- Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron D, Jones DR, Daly BD, Starnes SL, Hatter JE, Putnam JB. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. J Thorac Cardiovasc Surg. 2011 Sep;142(3):554-62. doi: 10.1016/j.jtcvs.2010.10.061. Epub 2011 Jul 2.
- Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, Meyers BF, DiPetrillo TA, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB Jr. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014 Aug 10;32(23):2456-62. doi: 10.1200/JCO.2013.53.4115. Epub 2014 Jun 30.
- Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, Heron DE, Hillman SL, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB; Alliance for Clinical Trials in Oncology. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. J Thorac Cardiovasc Surg. 2015 Mar;149(3):718-25; discussion 725-6. doi: 10.1016/j.jtcvs.2014.11.003. Epub 2014 Nov 13.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ACOSOG-Z4032
- CDR0000422346 (Registrierungskennung: NCI Physician Data Query)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lungenkrebs
-
Hal C CharlesAbgeschlossenKonstriktive Bronchiolitis | Irak-Afganistan War Lung Injury SyndromeVereinigte Staaten
-
Joseph MccuneEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterBeendetLupus erythematodes, systemisch | Systemische Vaskulitis | Lungenerkrankung mit systemischer Sklerose | Isolierte Angiitis des zentralen Nervensystems | Lung Disease Interstitial DiffusVereinigte Staaten
Klinische Studien zur Operation
-
Columbia UniversityAbbott NutritionRekrutierungHerzfehler | Darm-Mikrobiom | ErnährungsmangelVereinigte Staaten
-
Royal Surrey County Hospital NHS Foundation TrustUnbekanntEierstockkrebs | Eileiterkrebs | Bauchfellkrebs | Eierstock-Neoplasma | Eierstock-Neoplasma EpithelialVereinigtes Königreich
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekrutierungArthrose, HüfteVereinigtes Königreich
-
NYU Langone HealthNoch keine RekrutierungEntzündliche DarmerkrankungenVereinigte Staaten
-
University of Colorado, DenverRekrutierungVerbesserte Erholung nach der Operation | Gynäkologische ErkrankungVereinigte Staaten
-
Mayo ClinicBeendetGastroösophagealer Reflux | Hernie, Hiatal | Umfragen und Fragebögen | FundoplikatioVereinigte Staaten
-
NYU Langone Health7D Surgical Inc.ZurückgezogenSkoliose | Spinale Stenose | Spondylolisthese
-
Dr. Faruk SemizAnmeldung auf Einladung
-
Radboud University Medical CenterAktiv, nicht rekrutierendProstatakrebs | LymphknotenmetastasenNiederlande
-
University of TriesteAbgeschlossen